Rigel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Rigel Pharmaceuticals has a total shareholder equity of $-28.6M and total debt of $103.2M, which brings its debt-to-equity ratio to -360.2%. Its total assets and total liabilities are $117.2M and $145.9M respectively.
Key information
-360.2%
Debt to equity ratio
US$103.19m
Debt
| Interest coverage ratio | n/a |
| Cash | US$56.93m |
| Equity | -US$28.64m |
| Total liabilities | US$145.87m |
| Total assets | US$117.23m |
Recent financial health updates
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?
Nov 02Recent updates
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates
Mar 06Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net
Feb 01An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued
Jan 14Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive
Nov 30Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?
Nov 02Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines
Sep 06It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year
May 12Rigel Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 05Analysts Just Published A Bright New Outlook For Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL)
Feb 22Financial Position Analysis
Short Term Liabilities: RIGL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RIGL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RIGL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RIGL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RIGL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RIGL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.